Mild chemo with immunotherapy for older adults with advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer (stage IIIB, IIIC, or IV) or cancer that has come back and can't be treated with curative intent.
- You are 70 or older, or have health issues (frailty) that make standard treatment harder.
- Your cancer's PD-L1 level must be less than 50% — this is a protein that helps decide if immunotherapy can work.
- You cannot have certain gene mutations that have approved targeted therapies (testing is optional for one type).
- You must be able to do daily activities with some help (ECOG performance status 0 to 3).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new combination of an immunotherapy drug (QL1706) with chemotherapy and a special radiation technique (Quad Shot) for people with advanced non-small cell lung cancer that has spread. The goal is to see if this combination can help control the cancer better than standard treatment.
This trial tests a combination of chemotherapy and immunotherapy for people 65 or older with metastatic non-small cell lung cancer that has not been treated before and expresses PD-L1. It aims to see if this treatment can help control the cancer.
This trial is testing a combination of an oral chemotherapy pill (vinorelbine) and an immunotherapy drug (PD-1 inhibitor) for people aged 65 and older with advanced non-small cell lung cancer who have not had treatment before. The goal is to see if this approach can help control the cancer with fewer side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.